AA
AVBP icon

ALPS Advisors’s ArriVent BioPharma AVBP Stock Holding History

ALPS Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$830K Buy
35,986
+2,090
+6% +$47.2K ﹤0.01% 609
2025
Q4 		$682K Buy
+33,896
New +$706K ﹤0.01% 659
2025
Q2 		– Sell
-25,167
Closed -$465K – 1063
2025
Q1 		$465K Sell
25,167
-2,085
-8% -$51K ﹤0.01% 603
2024
Q4 		$726K Sell
27,252
-181
-0.7% -$5.2K ﹤0.01% 552
2024
Q3 		$645K Buy
27,433
+1,294
+5% +$29.4K ﹤0.01% 583
2024
Q2 		$485K Buy
+26,139
New +$466K ﹤0.01% 581

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ALPS Advisors's AVBP Position: Q1 2026 in Review

ALPS Advisors increased its ArriVent BioPharma (AVBP) stake by 6.2% in Q1 2026, buying an estimated $47.2K and bringing the position to 35,986 shares worth $830K. The position accounts for ﹤0.01% of the portfolio, ranked #609.

ALPS Advisors first reported a position in AVBP in Q2 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • ALPS Advisors held 35,986 shares of ArriVent BioPharma worth $830K as of Q1 2026.
  • ALPS Advisors bought 2,090 ArriVent BioPharma shares in Q1 2026, an estimated $47.2K.
  • ArriVent BioPharma made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #609 holding.
  • ALPS Advisors first reported a position in ArriVent BioPharma in Q2 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.